Gregory S Raskin Net Worth

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Gregory Raskin YMAB stock SEC Form 4 insiders trading

Gregory has made over 1 trades of the Y-Mabs Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Gregory sold 5,882 units of YMAB stock worth $157,049 on 29 August 2019.

The largest trade Gregory's ever made was selling 5,882 units of Y-Mabs Therapeutics Inc stock on 29 August 2019 worth over $157,049. On average, Gregory trades about 2,941 units every 0 days since 2019.

You can see the complete history of Gregory Raskin stock trades at the bottom of the page.

What's Gregory Raskin's mailing address?

Gregory's mailing address filed with the SEC is C/O MEMORIAL SLOAN KETTERING CANCER, CENTER, 1275 YORK AVENUE, BOX 524, NEW YORK, NY, 10065.

Insiders trading at Y-Mabs Therapeutics Inc

Over the last 6 years, insiders at Y-Mabs Therapeutics Inc have traded over $85,284,951 worth of Y-Mabs Therapeutics Inc stock and bought 1,819,126 units worth $23,554,756 . The most active insiders traders include James Healy, Thomas Gad, and Johan Wedell Wedellsborg. On average, Y-Mabs Therapeutics Inc executives and independent directors trade stock every 14 days with the average trade being worth of $494,414. The most recent stock trade was executed by Torben Lund Hansen on 28 August 2024, trading 50,000 units of YMAB stock currently worth $219,000.

What does Y-Mabs Therapeutics Inc do?

y-mabs is late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. the company has a broad and advanced product pipeline, including 2 pivotal-stage product candidates - naxitamab and omburtamab - which target tumors that express gd2 and b7-h3, respectively. our mission is to become the world leader in developing antibody-based cancer products that address clear unmet needs in pediatric oncology. with the right partnerships and collaboration, we envision expanding our capabilities to treat adults - changing the course of cancer and its outcome.

Complete history of Gregory Raskin stock trades at Y-Mabs Therapeutics Inc

Y-Mabs Therapeutics Inc executives and stock owners

Y-Mabs Therapeutics Inc executives and other stock owners filed with the SEC include:

• Dr. Claus Juan Møller San Pedro M.D., Ph.D.,
  CEO & Director
• Claus Moller-San Pedro,
  Chief Executive Officer, Director
• Thomas Gad,
  Chairman of the Board, President, Founder, Head of Business Development and Strategy
• Thomas Gad,
  Founder, Chairman, Pres and Head of Bus. Devel. & Strategy
• Bo Kruse,
  Chief Financial Officer, Executive Vice President, Treasurer, Secretary, Director
• Bo Kruse,
  Exec. VP, Sec., Treasurer & CFO
• David Gill,
  Independent Director
• James Healy,
  Independent Director
• Ashutosh Tyagi,
  Independent Director
• Gerard Ber,
  Independent Director
• Johan Wedell-Wedellsborg,
  Independent Director
• Torben Lund-Hansen,
  Senior Vice President, Chief Technical Officer
• Steen Lisby,
  Senior Vice President, Chief Medical Officer
• Philip Herman,
  Senior Vice President and Chief Commercial Officer
• Mahiuddin Ahmed,
  Senior Vice President, Chief Scientific Officer
• Joris Wilms,
  Chief Operating Officer, Senior Vice President
• Sue Smith,
  Sr. VP & Chief Commercial Officer
• Dr. Torben Lund-Hansen,
  Sr. VP & Chief Technical Officer
• Joris Wiel Jan Wilms,
  Sr. VP & COO
• Dr. Vignesh Rajah,
  Sr. VP & Chief Medical Officer
• Dr. Steen Lisby M.D., M.Sc.,
  Sr. VP & Chief Scientific Officer
• Peter P. Pfreundschuh,
  CFO and Treasurer
• Gregory S Raskin,
  Director
• Ashu Tyagi,
  Director
• Mary Tagliaferri,
  Director
• Laura Hamill,
  Director
• Vignesh Rajah,
  SVP & CHIEF MEDICAL OFFICER
• Biotech Ap S Wg,
  Director
• Susan Laura Smith,
  SVP & CHIEF COMMERCIAL OFFICER
• Michael J Rossi,
  PRESIDENT & CEO